Breast Cancer

Risks outweigh benefits for extended adjuvant endocrine therapy after breast cancer

Extending anastrozole therapy by five years provides no benefit over a two-year extension in women with hormone-receptor–positive breast cancer who have already received five years of adjuvant endocrine therapy, new results show. As well,  the longer duration of treatment was associated with a higher risk of bone fractures (6.3% v 4.7%). The Secondary Adjuvant Long-Term ...

Already a member?

Login to keep reading.

© 2022 the limbic